Anika Therapeutics Inc expected to post a loss of 1 cent a share - Earnings Preview

Anika Therapeutics

29/10/2024 13:46

* Anika Therapeutics Inc  ANIK.OQ   ANIK.O  is expected
to show a
rise in quarterly revenue when it reports  results on October 31
for the period ending September 30 2024
    * The Bedford Massachusetts-based  company is expected to
report a
1.5% increase in revenue to $42.083 million from $41.47 million
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Anika Therapeutics Inc
is for
a loss of 1 cent per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $34.50​, above​ its last closing price
of $24.66. ​​​

This summary was machine generated October 29 at 13:45 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)